Losartan and Bupropion Interaction

Why This Interaction Matters

Losartan is one of the most prescribed angiotensin II receptor blockers (ARBs) in the United States, with over 50 million dispensed prescriptions annually. Bupropion, used for major depressive disorder, seasonal affective disorder, and smoking cessation, ranks among the top 25 antidepressants by volume. Overlap is common. A patient starting bupropion while already on losartan for hypertension, or vice versa, faces two pharmacologic considerations that work in the same unfavorable direction: reduced losartan activation and a direct pressor effect from bupropion.

The Scale of Co-Prescribing

Analysis of Medicare Part D claims data shows ARBs and antidepressants are co-prescribed in roughly 18% of hypertensive adults over age 60 1. Bupropion carries a specific interaction flag with losartan in the Lexicomp, Micromedex, and Clinical Pharmacology databases, rated as moderate severity. That rating means the combination is not contraindicated but does warrant monitoring.

What Makes Losartan Different from Other ARBs

Unlike valsartan or irbesartan, losartan is a prodrug. Approximately 14% of an oral dose is converted by hepatic cytochrome P450 enzymes (primarily CYP2C9, with contributions from CYP3A4 and CYP2D6) into the active metabolite E-3174, which is 10 to 40 times more potent at blocking the angiotensin II type 1 (AT1) receptor than losartan itself 2. Any drug that impairs this conversion could blunt the antihypertensive response.

The CYP2D6 Mechanism

Bupropion and its primary metabolite hydroxybupropion are potent inhibitors of CYP2D6, with in vivo inhibition comparable to quinidine 3. The FDA label for bupropion hydrochloride extended-release states that co-administration with CYP2D6 substrates may require dose reduction of the substrate 4.

How CYP2D6 Fits into Losartan Metabolism

CYP2C9 is the dominant enzyme for losartan-to-E-3174 conversion. CYP3A4 contributes a secondary pathway. CYP2D6 plays a smaller but measurable role. A 2001 study in Clinical Pharmacology & Therapeutics showed that CYP2D6 poor metabolizers had modestly reduced E-3174 formation compared with extensive metabolizers, though the difference was clinically minor in most subjects 5.

The practical implication: bupropion's CYP2D6 blockade alone is unlikely to produce a dramatic reduction in E-3174 levels. The concern becomes more relevant in patients who are also CYP2C9 poor metabolizers (roughly 1-3% of Caucasians carry *3/*3 genotype) or who take other CYP2C9 inhibitors such as fluconazole or amiodarone 6.

When Phenoconversion Tips the Balance

"Phenoconversion" describes the state where a genetically normal (extensive) metabolizer functions as a poor metabolizer because of drug-induced enzyme inhibition. A patient who is a CYP2C9 intermediate metabolizer and simultaneously receives bupropion (blocking CYP2D6) loses two of the three metabolic pathways for E-3174 formation. In this subset, losartan efficacy may decline enough to show up on a home blood pressure log as readings 5-10 mmHg above the expected target 7.

Bupropion's Direct Effect on Blood Pressure

Separate from the CYP interaction, bupropion raises blood pressure in a dose-dependent manner. This is a pharmacodynamic (PD) concern that compounds the pharmacokinetic (PK) interaction.

Clinical Trial Data

In the Contrave (naltrexone/bupropion) cardiovascular outcomes trial, mean systolic blood pressure increased by 1-2 mmHg above placebo during the first 8 weeks of therapy 8. The bupropion FDA label reports that sustained hypertension (defined as systolic blood pressure >160 mmHg or diastolic >100 mmHg) occurred in approximately 6% of patients receiving bupropion SR 300 mg daily, compared to 2% on placebo 4.

The Combined Scenario

A patient on losartan 50 mg daily who begins bupropion XL 300 mg faces two concurrent pressures on blood pressure control: a modest reduction in losartan's active metabolite formation and a direct norepinephrine/dopamine-mediated pressor effect from bupropion. Neither effect in isolation is large. Together, they can push a well-controlled patient into the 140-150 mmHg systolic range.

The ACC/AHA 2017 Hypertension Guideline defines elevated blood pressure as systolic 120-129 mmHg without elevated diastolic, and Stage 1 hypertension as 130-139/80-89 mmHg 9. A 5-10 mmHg rise can cross a staging threshold and trigger a change in management.

Monitoring Protocol

Blood pressure monitoring is the cornerstone of managing this combination safely. The approach does not need to be complicated, but it does need to be consistent.

Baseline Assessment

Before adding bupropion to an existing losartan regimen (or before adding losartan in a patient already on bupropion), obtain at least three seated blood pressure readings over one week. Record the average. This becomes the reference point for detecting change.

Follow-Up Schedule

Check blood pressure at 2 weeks and again at 4 weeks after the second drug is introduced. Bupropion reaches steady state in approximately 8 days for the XL formulation, so the 2-week mark captures the full pharmacokinetic effect. If readings remain within 5 mmHg of baseline, the standard monitoring schedule (every 3-6 months) can resume.

Red Flags Requiring Action

A sustained systolic increase of 10 mmHg or more above baseline, confirmed on at least two separate days, should prompt clinical reassessment. Options include increasing losartan from 50 mg to 100 mg daily, adding a low-dose thiazide if not already present, or switching to an ARB with less CYP dependence.

Dose Adjustment Strategies

Most patients will not need dose changes. For those who do, the adjustments follow a logical sequence.

Step 1: Optimize Losartan Dose

If the patient is on losartan 25 mg or 50 mg and blood pressure has risen, the first move is titrating to 100 mg daily (the maximum FDA-approved dose for hypertension). The losartan label supports once-daily or twice-daily dosing 10. This additional substrate load can partially compensate for reduced CYP2D6-mediated conversion by relying more heavily on CYP2C9 and CYP3A4 pathways.

Step 2: Consider an ARB Switch

If losartan 100 mg daily with a diuretic still fails to achieve target blood pressure, switching to valsartan (80-320 mg daily) or irbesartan (150-300 mg daily) removes the prodrug variable entirely. Both are active parent compounds that do not require CYP-mediated conversion for their antihypertensive effect 2.

Step 3: Reassess Bupropion Necessity

In rare cases where blood pressure proves difficult to control and the patient has alternative antidepressant options, a switch from bupropion to an SSRI (which carries a neutral-to-mild blood pressure effect) may be appropriate. This decision belongs to the prescribing psychiatrist and should weigh depression control against cardiovascular risk.

Special Populations

CYP2C9 Poor Metabolizers

Patients of Middle Eastern or African ancestry carry CYP2C9 variant alleles (*2, *3, *5, *6, *8, *11) at higher combined frequencies than European-ancestry populations 6. In a CYP2C9 poor metabolizer, the addition of bupropion (blocking CYP2D6) leaves CYP3A4 as the primary remaining pathway for E-3174 formation. These patients benefit most from proactive blood pressure monitoring or from using a non-prodrug ARB from the start.

Older Adults

Adults over 65 are more likely to be on both an ARB and an antidepressant. Age-related decline in hepatic CYP activity compounds enzyme inhibition. The Beers Criteria do not flag the losartan-bupropion combination specifically, but they do recommend blood pressure monitoring whenever a new psychotropic is added in older adults 11.

Patients with Renal Impairment

Losartan clearance is not significantly altered in renal impairment because elimination is primarily hepatic. Bupropion metabolites (including the CYP2D6-inhibiting hydroxybupropion) accumulate in renal impairment, increasing the degree of CYP2D6 inhibition 4. In patients with eGFR <30 mL/min, bupropion dose reduction (to 150 mg daily or every other day) limits both the pressor effect and the CYP2D6 inhibition.

Seizure Threshold: A Separate Concern

Bupropion lowers the seizure threshold in a dose-dependent fashion. The risk is approximately 0.4% at 450 mg/day 4. Losartan does not affect seizure threshold. This interaction axis is unidirectional and does not compound with losartan. It is mentioned here because patients and prescribers sometimes conflate all drug interaction warnings, and it is worth clarifying that the seizure risk is bupropion-specific and independent of the ARB.

Patient Counseling Points

Patients taking both medications should know three things. First, the combination is generally safe and does not require stopping either drug. Second, home blood pressure monitoring for the first month after starting the combination provides early warning if control slips. Third, symptoms like persistent headache, visual changes, or chest pressure while on both medications should prompt a same-day blood pressure check and a call to their prescriber.

A reasonable counseling script: "These two medications can be used together. Bupropion may slightly reduce how well losartan works and can raise blood pressure on its own. Check your blood pressure at home for the first four weeks. If the top number goes above [patient-specific target], contact us."

Pharmacogenomic Testing: When It Helps

Commercial pharmacogenomic panels (GeneSight, OneOme, Tempus) report CYP2C9 and CYP2D6 genotypes. For a patient on losartan and bupropion whose blood pressure is unexpectedly difficult to control, a pharmacogenomic test can clarify whether reduced CYP2C9 activity is compounding the bupropion-induced CYP2D6 blockade. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for CYP2C9 and losartan 12. If the patient carries CYP2C9 *1/*3 or *2/*3, switching to a non-prodrug ARB is the straightforward fix.

Testing is not necessary for every patient on this combination. It becomes cost-effective when blood pressure remains above target despite losartan 100 mg daily and adherence has been confirmed.

Summary of Clinical Actions

| Scenario | Action | |---|---| | Adding bupropion to stable losartan therapy | Check BP at baseline, 2 weeks, and 4 weeks | | BP rises 5-10 mmHg above baseline | Titrate losartan to 100 mg daily | | BP rises >10 mmHg despite losartan 100 mg | Switch to valsartan or irbesartan | | Known CYP2C9 poor metabolizer | Start with a non-prodrug ARB | | eGFR <30 mL/min | Reduce bupropion dose; monitor BP weekly for 4 weeks |

The target for most adults is systolic blood pressure <130 mmHg per the 2017 ACC/AHA guideline 9.